Biogen Inc., US09062X1037

Biogen stock: Five-year lecanemab data show slower progression

Published on 11/17/2026 at 22:03 | Editorial responsibility: Rafael MĂĽller, Editor-in-Chief AD HOC NEWS
Biogen stock follows new five-year lecanemab results presented at CTAD 2026. The findings point to slower Alzheimer’s progression with continued treatment.

Long-Term Lecanemab Results

  • Five-year Clarity AD extension results linked continuous lecanemab treatment with slower disease progression than natural-history comparisons.
  • The findings add long-term evidence to Biogen's Alzheimer portfolio and were presented at CTAD 2026.
  • No new safety findings were observed during five years of continuous treatment.
Biogen Inc., US09062X1037, Illustration mit AI erstellt.

Biogen and Eisai reported new five-year Clarity AD extension results on November 16, 2026, linking continuous lecanemab treatment with slower progression in early Alzheimer’s disease. The findings were presented at the Clinical Trials on Alzheimer’s Disease conference, according to the Biogen investor release.

Five-Year Clarity AD Findings

The Phase 3 Clarity AD study and its long-term extension involved 1,795 patients with early Alzheimer’s disease. Among patients who received five years of continuous treatment, the difference in mean CDR-SB change versus the ADNI natural-history comparison reached 2.05 points at five years.

Lecanemab reduced the relative risk of progression to the next disease stage by 36 percent versus ADNI. The relative risk of progression from early Alzheimer’s disease to moderate or severe dementia was 49 percent lower in the reported assessment.

Evidence For Biogen's Alzheimer Portfolio

In the low-tau subgroup, 66 percent of patients showed no decline on the CDR-SB after five years, while 62 percent showed improvement. On the ADAS-Cog14 cognition scale, 52 percent showed improvement, and 62 percent improved on the measure of daily living activities.

The companies reported no new safety findings during five years of continuous treatment. Amyloid-related imaging abnormalities with edema or effusion occurred most frequently during the first six months.

Stock Quote And Investor Context

Biogen stock traded at 227.93 euros on Lang & Schwarz at 10:00 p.m. CET on Tuesday, November 17. The company and Eisai jointly develop and commercialize lecanemab, with Eisai leading global development and regulatory submissions.

Biogen Inc. Key Facts

  • Company: Biogen Inc.
  • ISIN: US09062X1037
  • Ticker: BIIB
  • Home exchange: Nasdaq
  • Lang & Schwarz quote: 227.93 euros on November 17, 2026, at 10:00 p.m. CET

The wider Nasdaq market provides the relevant market setting for the U.S.-listed company.

More news and analyses on Biogen stock

Disclaimer...
en | US09062X1037 | BIOGEN INC. | boerse | 70528676 | bgmi